ABLE Financial Group LLC Makes New $537,000 Investment in Zoetis Inc. $ZTS

Key Points

• ABLE Financial Group LLC invested approximately $537,000 in Zoetis Inc. during the second quarter, acquiring 3,441 shares of the company.
• Several institutional investors have increased or initiated positions in Zoetis; however, 92.80% of the company's stock is currently owned by institutional investors.
• Analysts have mixed ratings on Zoetis, with five giving it a Buy rating and four a Hold rating, and an average target price of $200.88.

ABLE Financial Group LLC acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,441 shares of the company's stock, valued at approximately $537,000.

Other hedge funds also recently modified their holdings of the company. Nuveen LLC purchased a new position in shares of Zoetis in the 1st quarter worth about $616,375,000. Sarasin & Partners LLP purchased a new stake in shares of Zoetis during the 1st quarter valued at about $339,111,000. Mackenzie Financial Corp raised its holdings in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after buying an additional 1,782,110 shares during the period. GAMMA Investing LLC raised its holdings in shares of Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after buying an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC raised its holdings in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on ZTS. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Price Performance

NYSE ZTS traded down $1.15 during trading hours on Monday, reaching $144.73. 2,044,648 shares of the company's stock were exchanged, compared to its average volume of 2,375,084. The stock has a market cap of $64.14 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.88. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a fifty day moving average of $151.03 and a 200-day moving average of $156.27. Zoetis Inc. has a one year low of $139.70 and a one year high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.